{
  "id": 16882423,
  "title": "Biogen beats Q3 estimates, raises guidance floor on growth",
  "url": "https://urgent.news/2026/10/28/biogen-beats-q3-estimates-raises-guidance-floor-on-growth",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-28T10:14:48.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/earnings/biogen-beats-q3-estimates-raises-guidance-floor-on-growth-4978168"
  },
  "original_language": "en",
  "account": "Biogen Inc (NASDAQ:BIIB) surpassed earnings per share estimates in Q3, reporting $2.62 compared to the consensus of $2.02. Revenue increased to $2.8 billion, up 11% year-over-year. The Growth Portfolio's revenue grew 49% YoY to $1.26 billion, boosted by Apellis products and existing franchises. Biogen raised its lower 2026 EPS guidance range to $12.20-$13.00, surpassing the analyst consensus of $12.36. CEO Christopher A. Viehbacher expressed enthusiasm about the company's return to growth, noting the strength of the Growth Portfolio, including Apellis products, driving double-digit revenue growth. SPINRAZA revenue increased 23% to $461 million, while LEQEMBI sales rose 67% YoY to $202 million. SYFOVRE generated $191 million with 18% volume growth, and SKYCLARYS revenue climbed 34% to $178 million. Rare disease revenue grew 27% to $676 million, and Apellis-related revenue totaled $243 million. R&D expenses increased 31% to $567 million, with $284 million in acquired in-process R&D charges. Biogen anticipates a mid-single digit revenue increase for 2026.",
  "summary": null,
  "key_points": [
    "Biogen beats Q3 EPS estimates with $2.62 per share",
    "Revenue grows 11% YoY to $2.8 billion",
    "Raises 2026 EPS guidance range to $12.20-$13.00"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}